What are the Effects of Levofloxacin Mesylate and Sodium Chloride Injection?

Methanesulfonic acid levofloxacin and sodium chloride injection belongs to antibiotics, mainly used to treat diseases caused by bacterial infections, such as acute prostatitis, epididymitis, cervicitis, adnexitis, and lymphangitis. During the injection of methanesulfonic acid levofloxacin and sodium chloride, symptoms such as abdominal distension, nausea, vomiting, loss of appetite, and insomnia may occur. Therefore, rational use of drugs is required. Let's take a look at what are the effects of methanesulfonic acid levofloxacin and sodium chloride injection?

Methanesulfonic acid levofloxacin and sodium chloride injection belongs to quinolone antibiotics, mainly used for moderate and severe infections caused by sensitive bacteria, including acute bronchitis, acute phase of chronic bronchitis, diffuse bacterial bronchitis, bronchiectasis, pneumonia with concurrent infection, tonsillitis, pyelonephritis, complicated urinary tract infection, acute prostatitis, acute epididymitis, cervicitis, adnexitis, pelvic inflammatory disease, contagious impetigo, cellulitis, lymphangitis, lymphadenitis, subcutaneous abscess, and perianal abscess. It can also be used to treat bacterial dysentery, infectious enteritis, Salmonella enteritis, typhoid fever, and paratyphoid fever, as well as septicemia, granulocytopenia, and low immunity. Note that patients with allergies to quinolone drugs, pregnant and lactating women, and patients under 18 years of age are contraindicated.

During the administration of methanesulfonic acid levofloxacin and sodium chloride injection, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and abdominal distension may occur. Neurological symptoms such as insomnia, dizziness, and headache may also appear. Skin reactions such as rash, itching, erythema, redness and itching at the injection site, or phlebitis may occur. Transient abnormal liver function, such as increased blood transaminase and total serum bilirubin, may also be observed. The incidence of these adverse reactions ranges from 0.1 to 5%. Occasional elevations in blood urea nitrogen, fatigue, fever, palpitations, and altered taste sensation may occur, but these are generally tolerable and disappear rapidly after the end of the treatment course.

1. This preparation is specifically for intravenous drip administration, with a drip time of at least 60 minutes for every 100ml. This preparation should not be mixed with other drugs in the same bottle for intravenous drip administration or administered through the same intravenous infusion tube.

2. Dosage should be reduced or used with caution in patients with renal dysfunction.

3. Patients with central nervous system diseases and a history of epilepsy should use this medication with caution.